Wood, GE;
Ledermann, JA;
(2022)
Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer.
Best Practice & Research Clinical Obstetrics & Gynaecology
, 78
pp. 64-73.
10.1016/j.bpobgyn.2021.09.002.
Preview |
Text
YBEOG-S-21-00243.pdf - Accepted Version Download (1MB) | Preview |
Abstract
Cytoreductive surgery is the mainstay of treatment for high-grade epithelial ovarian cancer. Although for early stage disease outcomes following surgery alone are good, the risk of recurrence necessitates adjuvant chemotherapy for the majority of patients. Post-operative chemotherapy in advanced-stage disease, or neoadjuvant chemotherapy followed by surgery has improved progression-free survival (PFS) and overall survival (OS). However, despite the use of chemotherapy, the rate of recurrence remains high. In recent years, there has been considerable increase in knowledge regarding the biology of ovarian cancer, which has led to a journey of drug discovery, facilitating the use of novel targeted agents such as VEGF inhibitors and, more recently, PARP inhibitors in the first-line treatment of ovarian cancer. Here, we outline the current evidence-based guidance for systemic therapies in ovarian cancer and highlight the ongoing research to improve patient outcome.
Archive Staff Only
 |
View Item |
